Division of Cardiology and Critical Care, University of Alberta, Edmonton, Alberta, Canada.
Crit Care Med. 2013 Sep;41(9):2080-7. doi: 10.1097/CCM.0b013e31828a67b2.
To assess whether systemic inflammatory response syndrome is associated with morbidity and mortality in ST-elevation myocardial infarction.
Secondary analysis of multicenter randomized controlled trials.
Complement and reduction of infarct size after angioplasty or lytics project patients (n=1,903) with ST-elevation myocardial infarction undergoing fibrinolysis or mechanical reperfusion.
None.
The prevalence of systemic inflammatory response syndrome was described in the 1,186 patients (64.4%) with data available for all systemic inflammatory response syndrome criteria. Using multiple imputations for the 1,843 patients (96.8%) with available endpoints, we compared the 90-day prevalence of death, shock, heart failure, or stroke between patients with and without systemic inflammatory response syndrome at presentation and at 24 hours post admission. Systemic inflammatory response syndrome was defined as ≥2 of 1) heart rate>90 beats/min, 2) respiratory rate>20 breaths/min, 3) body temperature>38 or <36°C, or 4) leukocyte count>12 or<4×10/L. At presentation, 25.0% of patients met systemic inflammatory response syndrome criteria; at 24 hours, 8.1% of patients met systemic inflammatory response syndrome criteria. The primary outcome was more frequent among patients with systemic inflammatory response syndrome at presentation (31.0% vs 16.7%; adjusted hazard ratio, 1.78 [95% CI, 1.35-2.34]; p<0.001) and at 24 hours (36.7% vs 11.1%; adjusted hazard ratio, 2.84 [95% CI, 2.03-3.97]; p<0.001). Mortality at 90 days was also higher among patients with systemic inflammatory response syndrome at either time point. Each additional systemic inflammatory response syndrome criterion was independently associated with 90-day outcomes at the time of presentation (adjusted hazard ratio, 1.41 per systemic inflammatory response syndrome criteria [95% CI, 1.24-1.61]; p<0.001) and at 24 hours (adjusted hazard ratio, 1.72 per systemic inflammatory response syndrome criteria [95% CI, 1.47-2.01]; p<0.001).
The diagnosis of systemic inflammatory response syndrome and the cumulative number of systemic inflammatory response syndrome criteria were independently associated with 90-day clinical outcomes in a population of patients with ST-elevation myocardial infarction. The independent association of this simple composite measure of the inflammatory response with outcomes underscores the importance of the clinical inflammatory response in ST-elevation myocardial infarction.
评估全身炎症反应综合征与 ST 段抬高型心肌梗死患者发病率和死亡率的关系。
多中心随机对照试验的二次分析。
接受溶栓或机械再灌注治疗的 ST 段抬高型心肌梗死患者(n=1903)中,补体和血管成形术或溶栓后梗死面积缩小项目患者(n=1903)。
无。
对 1186 例患者(64.4%)进行了全身炎症反应综合征的流行情况描述,这些患者所有全身炎症反应综合征标准的数据均可用。对于可获得终点的 1843 例患者(96.8%),我们使用多重插补法,比较入院时和入院后 24 小时有和无全身炎症反应综合征患者的 90 天死亡率、休克、心力衰竭或脑卒中发生率。全身炎症反应综合征定义为:1)心率>90 次/分;2)呼吸频率>20 次/分;3)体温>38 或<36°C;或 4)白细胞计数>12 或<4×10/L,满足其中 2 项以上。入院时,25.0%的患者符合全身炎症反应综合征标准;入院后 24 小时,8.1%的患者符合全身炎症反应综合征标准。主要结局在入院时(31.0%比 16.7%;调整后的危险比,1.78[95%CI,1.35-2.34];p<0.001)和入院后 24 小时(36.7%比 11.1%;调整后的危险比,2.84[95%CI,2.03-3.97];p<0.001)均更常见于全身炎症反应综合征患者。90 天死亡率在两个时间点均高于全身炎症反应综合征患者。在入院时(调整后的危险比,每增加一个全身炎症反应综合征标准为 1.41[95%CI,1.24-1.61];p<0.001)和入院后 24 小时(调整后的危险比,每增加一个全身炎症反应综合征标准为 1.72[95%CI,1.47-2.01];p<0.001),每个附加的全身炎症反应综合征标准与 90 天的临床结局独立相关。
全身炎症反应综合征的诊断和全身炎症反应综合征标准的累积数量与 ST 段抬高型心肌梗死患者的 90 天临床结局独立相关。这种简单的炎症反应综合指标与结局的独立相关性突出了炎症反应在 ST 段抬高型心肌梗死中的重要性。